Future of Merck cholesterol sales could hang on long-awaited study

(Reuters) - A nine-year, 18,000-patient study of Merck & Co's $4 billion Zetia and Vytorin cholesterol franchise is likely to show some benefit but keep open the question of whether it can significantly reduce heart attacks, strokes and death.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news